DOR Needs More Phase III Data To Gain Approval For OrBec
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says approval of orBec may be possible with positive results from a single confirmatory Phase III trial.
You may also be interested in...
FDA Rejects Dor Biopharma’s OrBec For GI Graft-Versus-Host Disease
In a “not approvable” letter, agency requests additional clinical trial data to show the drug is safe and effective.
FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.